Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Healthcare
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more

Recent & Breaking News (NYSE:TAK)

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

Business Wire September 15, 2020

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Metropolitan Detroit

Business Wire September 11, 2020

Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO(TM) (ixazomib) in Newly Diagnosed Multiple Myeloma

Business Wire September 9, 2020

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

Business Wire September 8, 2020

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

Business Wire August 25, 2020

National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease

Business Wire August 10, 2020

Novavax and Takeda Announce Collaboration for Novavax' COVID-19 Vaccine Candidate in Japan

GlobeNewswire August 7, 2020

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana

Business Wire August 6, 2020

Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial

PR Newswire August 3, 2020

Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

Business Wire August 1, 2020

Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year

Business Wire July 31, 2020

Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Business Wire July 30, 2020

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

Business Wire July 12, 2020

BioLife Plasma Services Announces Opening of a Plasma Collection Center in North Las Vegas

Business Wire July 8, 2020

Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners

Business Wire July 8, 2020

Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders

Business Wire June 16, 2020

Takeda Provides Updates on its Hemophilia Studies at WFH 2020, Reinforcing its Commitment to Putting Patients First and Supporting Personalized Care for People with Bleeding Disorders

Business Wire June 15, 2020

Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO(TM) (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy

Business Wire June 12, 2020

BioLife Plasma Services Announces Opening of Two Plasma Collection Centers in St. Louis Area

Business Wire June 11, 2020

Takeda to Divest OTC and Select Non-core Assets in Asia Pacific to Celltrion for up to $278 Million USD

Business Wire June 11, 2020